In this study, we aimed to determine the clinical implications of Romo1 expression in patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma treated with first-line tyrosine kinase inhibitors (TKIs). The gene discussed is EGFR; the disease is lung adenocarcinoma.